Clinical Laserthermia Systems AB (publ) (CLS-B) - Net Assets

Latest as of December 2025: Skr66.48 Million SEK ≈ $7.15 Million USD

Based on the latest financial reports, Clinical Laserthermia Systems AB (publ) (CLS-B) has net assets worth Skr66.48 Million SEK (≈ $7.15 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr76.49 Million ≈ $8.23 Million USD) and total liabilities (Skr10.00 Million ≈ $1.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Clinical Laserthermia Systems AB (publ) asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr66.48 Million
% of Total Assets 86.92%
Annual Growth Rate 18.56%
5-Year Change 213.83%
10-Year Change 289.61%
Growth Volatility 112.78

Clinical Laserthermia Systems AB (publ) - Net Assets Trend (2008–2025)

This chart illustrates how Clinical Laserthermia Systems AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore CLS-B total assets for the complete picture of this company's asset base.

Annual Net Assets for Clinical Laserthermia Systems AB (publ) (2008–2025)

The table below shows the annual net assets of Clinical Laserthermia Systems AB (publ) from 2008 to 2025. For live valuation and market cap data, see CLS-B market cap.

Year Net Assets Change
2025-12-31 Skr66.48 Million
≈ $7.15 Million
+1.21%
2024-12-31 Skr65.69 Million
≈ $7.07 Million
+50.91%
2023-12-31 Skr43.53 Million
≈ $4.68 Million
+453.44%
2022-12-31 Skr7.87 Million
≈ $846.40K
-62.87%
2021-12-31 Skr21.18 Million
≈ $2.28 Million
+52.10%
2020-12-31 Skr13.93 Million
≈ $1.50 Million
+99.06%
2019-12-31 Skr7.00 Million
≈ $752.99K
-85.95%
2018-12-31 Skr49.81 Million
≈ $5.36 Million
+50.95%
2017-12-31 Skr33.00 Million
≈ $3.55 Million
+93.37%
2016-12-31 Skr17.06 Million
≈ $1.84 Million
-12.32%
2015-12-31 Skr19.46 Million
≈ $2.09 Million
-38.37%
2014-12-31 Skr31.58 Million
≈ $3.40 Million
+21.03%
2013-12-31 Skr26.09 Million
≈ $2.81 Million
+52.62%
2012-12-31 Skr17.09 Million
≈ $1.84 Million
+57.83%
2011-12-31 Skr10.83 Million
≈ $1.17 Million
+4.57%
2010-12-31 Skr10.36 Million
≈ $1.11 Million
+56.26%
2009-12-31 Skr6.63 Million
≈ $713.34K
+80.23%
2008-12-31 Skr3.68 Million
≈ $395.79K
--

Equity Component Analysis

This analysis shows how different components contribute to Clinical Laserthermia Systems AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1297233500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr71.98 Million 103.32%
Other Comprehensive Income Skr1.85 Million 2.65%
Other Components Skr9.64 Million 13.83%
Total Equity Skr69.67 Million 100.00%

Clinical Laserthermia Systems AB (publ) Competitors by Market Cap

The table below lists competitors of Clinical Laserthermia Systems AB (publ) ranked by their market capitalization.

Company Market Cap
The Grob Tea Company Limited
NSE:GROBTEA
$11.58 Million
Telecom Plus PLC
LSE:TEP
$11.58 Million
Holand og Setskog Sparebank
OL:HSPG
$11.58 Million
Park & Bellheimer AG
F:PKB
$11.60 Million
Arcoma AB
ST:ARCOMA
$11.55 Million
Yelooo Integra Datanet Tbk PT
JK:YELO
$11.54 Million
iOThree Limited Ordinary Shares
NASDAQ:IOTR
$11.54 Million
Cielo Waste Solutions Corp
V:CMC
$11.53 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Clinical Laserthermia Systems AB (publ)'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 68,722,000 to 69,667,000, a change of 945,000 (1.4%).
  • Net loss of 41,612,000 reduced equity.
  • New share issuances of 35,043,000 increased equity.
  • Other comprehensive income decreased equity by 230,000.
  • Other factors increased equity by 7,744,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-41.61 Million -59.73%
Share Issuances Skr35.04 Million +50.3%
Other Comprehensive Income Skr-230.00K -0.33%
Other Changes Skr7.74 Million +11.12%
Total Change Skr- 1.38%

Book Value vs Market Value Analysis

This analysis compares Clinical Laserthermia Systems AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.28x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.14x to 1.28x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2008-12-31 Skr24.15 Skr3.45 x
2009-12-31 Skr0.14 Skr3.45 x
2010-12-31 Skr0.23 Skr3.45 x
2011-12-31 Skr0.21 Skr3.45 x
2012-12-31 Skr1.00 Skr3.45 x
2013-12-31 Skr304.68 Skr3.45 x
2014-12-31 Skr370.43 Skr3.45 x
2015-12-31 Skr191.86 Skr3.45 x
2016-12-31 Skr147.98 Skr3.45 x
2017-12-31 Skr233.82 Skr3.45 x
2018-12-31 Skr314.28 Skr3.45 x
2019-12-31 Skr40.39 Skr3.45 x
2020-12-31 Skr63.07 Skr3.45 x
2021-12-31 Skr75.78 Skr3.45 x
2022-12-31 Skr21.29 Skr3.45 x
2023-12-31 Skr13.63 Skr3.45 x
2024-12-31 Skr6.24 Skr3.45 x
2025-12-31 Skr2.69 Skr3.45 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Clinical Laserthermia Systems AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -59.73%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -237.96%
  • • Asset Turnover: 0.23x
  • • Equity Multiplier: 1.10x
  • Recent ROE (-59.73%) is above the historical average (-174.05%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2008 -18.24% -447.33% 0.03x 1.50x Skr-1.04 Million
2009 -29.83% -988.51% 0.02x 1.24x Skr-2.64 Million
2010 -48.01% -1418.90% 0.03x 1.14x Skr-6.01 Million
2011 -64.40% -1992.87% 0.03x 1.20x Skr-8.06 Million
2012 -74.28% -10311.36% 0.01x 1.17x Skr-14.41 Million
2013 -70.24% -152708.33% 0.00x 1.12x Skr-20.93 Million
2014 -56.50% 0.00% 0.00x 1.17x Skr-21.00 Million
2015 -85.28% 0.00% 0.00x 1.14x Skr-18.54 Million
2016 -157.93% -740.97% 0.13x 1.60x Skr-28.66 Million
2017 -64.44% -3460.50% 0.01x 1.36x Skr-24.56 Million
2018 -65.96% -1817.20% 0.03x 1.16x Skr-37.84 Million
2019 -619.91% -3041.73% 0.04x 5.53x Skr-44.07 Million
2020 -415.99% -4349.77% 0.03x 3.19x Skr-59.33 Million
2021 -291.89% -2833.63% 0.03x 3.06x Skr-65.79 Million
2022 -766.63% -1127.31% 0.13x 5.37x Skr-71.58 Million
2023 -174.34% -964.49% 0.14x 1.26x Skr-84.37 Million
2024 -69.30% -253.54% 0.24x 1.14x Skr-54.50 Million
2025 -59.73% -237.96% 0.23x 1.10x Skr-48.58 Million

Industry Comparison

This section compares Clinical Laserthermia Systems AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $187,731,622
  • Average return on equity (ROE) among peers: -23.21%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Clinical Laserthermia Systems AB (publ) (CLS-B) Skr66.48 Million -18.24% 0.15x $11.57 Million
Acarix A/S (ACARIX) $15.12 Million -127.02% 0.21x $33.84 Million
Arcoma AB (ARCOMA) $48.66 Million 5.27% 0.68x $11.55 Million
Bactiguard Holding AB (publ) (BACTI-B) $387.11 Million -0.84% 0.62x $61.64 Million
BICO Group AB (BICO) $2.31 Million 0.00% 2.47x $159.82 Million
Boule Diagnostics AB (BOUL) $295.74 Million 7.87% 0.93x $14.38 Million
CellaVision AB (CEVI) $887.58 Million 17.25% 0.23x $311.10 Million
Chordate Medical Holding AB (CMH) $25.64 Million -77.06% 0.22x $29.05K
C-Rad AB (publ) (CRAD-B) $29.82 Million -34.38% 0.50x $86.08 Million
Duearity AB (DEAR) $-2.39 Million 0.00% 0.00x $331.97K

About Clinical Laserthermia Systems AB (publ)

ST:CLS-B Sweden Medical Devices
Market Cap
$11.57 Million
Skr107.52 Million SEK
Market Cap Rank
#26505 Global
#570 in Sweden
Share Price
Skr3.45
Change (1 day)
-4.83%
52-Week Range
Skr2.62 - Skr11.82
All Time High
Skr1089.26
About

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control trea… Read more